Lifesci Capital Has Bearish Forecast for VRDN Q3 Earnings

Key Points

• Lifesci Capital has downgraded its estimate for Viridian Therapeutics' Q3 2025 earnings per share from ($0.90) to ($1.03).
• Despite the downgrade, HC Wainwright restated a "buy" rating with a target price of $34.00, while other analysts have varied price targets for the stock, indicating mixed sentiments.
• Viridian Therapeutics recently reported a Q2 EPS of ($1.00), meeting analysts' consensus, with revenue showing a 4.2% year-over-year increase to $0.08 million.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at Lifesci Capital decreased their Q3 2025 earnings per share (EPS) estimates for Viridian Therapeutics in a report released on Wednesday, August 6th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($1.03) for the quarter, down from their prior forecast of ($0.90). The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. Lifesci Capital also issued estimates for Viridian Therapeutics' Q4 2025 earnings at ($1.06) EPS and FY2025 earnings at ($3.96) EPS.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, hitting analysts' consensus estimates of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same period last year, the company earned ($0.81) earnings per share. The business's revenue for the quarter was up 4.2% on a year-over-year basis.

VRDN has been the subject of several other research reports. Needham & Company LLC dropped their price objective on Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. JMP Securities dropped their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Wells Fargo & Company dropped their price objective on Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Finally, Royal Bank Of Canada reduced their price objective on Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating on the stock in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.00.

Viridian Therapeutics Price Performance

NASDAQ:VRDN traded down $0.61 during trading hours on Monday, hitting $18.24. 97,898 shares of the company's stock traded hands, compared to its average volume of 893,792. The firm has a market cap of $1.49 billion, a P/E ratio of -4.79 and a beta of 0.42. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $27.20. The business's fifty day simple moving average is $16.17 and its two-hundred day simple moving average is $15.20. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04.

Institutional Investors Weigh In On Viridian Therapeutics

Several institutional investors have recently bought and sold shares of VRDN. Deep Track Capital LP lifted its holdings in Viridian Therapeutics by 20.6% in the 4th quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock worth $86,701,000 after buying an additional 771,796 shares during the period. Tang Capital Management LLC raised its stake in Viridian Therapeutics by 11.1% during the fourth quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company's stock valued at $47,789,000 after buying an additional 250,000 shares during the last quarter. Paradigm Biocapital Advisors LP raised its stake in Viridian Therapeutics by 15.1% during the first quarter. Paradigm Biocapital Advisors LP now owns 2,095,079 shares of the company's stock valued at $28,242,000 after buying an additional 275,000 shares during the last quarter. Maverick Capital Ltd. raised its stake in Viridian Therapeutics by 0.4% during the first quarter. Maverick Capital Ltd. now owns 2,061,274 shares of the company's stock valued at $27,786,000 after buying an additional 7,368 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Viridian Therapeutics by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,740,614 shares of the company's stock worth $24,337,000 after purchasing an additional 20,089 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.